Home2019-12-21T11:22:17+11:00

Promise beyond cancer

Pioneering the development of nfP2X7 targeted therapeutics

Biosceptre is a biopharmaceutical company developing targeted therapeutics and immune-oncology products against non-functional P2X7 (nfP2X7), a cancer target that has been shown to be present on the majority of cancers. Our goal is to bring novel therapeutics to patients suffering from a wide range of malignancies.
READ MORE

What is nfP2X7?

SPECIFIC

to cancer cells

Non-functional P2X7 is a cell receptor highly specific to cancer cells.

TARGETED

to more than 20 cancer types

nfP2X7 is present on more than 20 of the most common cancers including: breast, lung, colorectal, and prostate.

THERAPEUTICS

with multiple modalities

Drug therapies in the pipeline include CAR-T and systemic antibodies.
READ MORE

Biosceptre Team

Biosceptre has built a team of highly talented and motivated people, focused on delivering our vision – a promise beyond cancer.”
Gavin Currie, CEO Biosceptre International
OUR TEAM

News & Media

MORE NEWS